Table 5

Kaplan–Meier probability of a cardiovascular adverse event by 3 years by subgroups

NPlacebo (n=1544)Salmeterol (n=1542)FP (n=1552)SFC (n=546)
Age
 <5570613.212.513.413.4
 55–64198820.218.820.717.4
 65–74270626.624.826.922.1
 ≥7578439.234.935.432.9
Sex
 Male468424.423.024.020.7*
 Female150023.421.925.321.0
Smoking status
 Current265422.222.022.420.5
 Former353025.823.325.920.9*
Baseline FEV1
 <30%94525.832.126.723.5
 30–<50%305625.720.725.423.4
 ≥50%218321.721.721.816.2*
Baseline CV treatment
 Yes253033.530.330.427.9*
 No365418.317.620.215.4
Prior MI
 Yes41949.154.441.044.1
 No576222.220.223.319.1
Baseline short-acting anticholinergics
 Yes371525.224.025.622.0
 No246922.721.022.418.9
  • * p<0.05 versus placebo.

  • CV, cardiovascular; FEV1, forced expiratory volume in 1 s; FP, fluticasone propionate; MI, myocardial infarction; SFC, salmeterol/fluticasone propionate combination.